ArticleBMC infectious diseases2025
The prevalence and influence of EBV infection in patients with severe fever with thrombocytopenia syndrome.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSevere fever with thrombocytopenia (SFTS) is a fatal emerging infectious disease. Co-infection, mainly with bacterial and fungal infections, in association with poorer outcomes in SFTS, but few studies have examined on viral infections. We aimed to investigate the prevalence of Epstein‒Barr virus (EBV) infection and its effects on the clinical features and mortality in patients with SFTS.
methodsWe retrospectively reviewed 104 patients with confirmed SFTS between 2011 and 2025, and analyzed their laboratory test results and clinical data.
resultsOf 104 SFTS patients, 48.10% had EBV infection. Compared to those without EBV infection, these patients were more likely to have bacterial infection in blood (p = 0.027), lower white blood cell (p < 0.001) and neutrophil counts (p = 0.019), lower serum calcium (p = 0.043), and higher alanine aminotransferase (p = 0.013), adenosine deaminase (p = 0.018), and urinary protein (p = 0.005). Mortality rates were higher in EBV-infected patients (7 [14%] vs. 4 [7.4%], p = 0.275), though not statistically significant. In this study, decreased WBC count and elevated ALT level were independently associated with EBV infection in SFTS patients (OR = 0.391 [95% CI, 0.233-0.657] and 1.006 [95% CI, 1.001-1.011], both p < 0.05).
conclusionsSFTS patients are at high risk for EBV infection. Those with EBV infection exhibit more severe clinical manifestations, although short-term survival does not differ significantly. Decreased WBC count and elevated ALT are risk factors for EBV infection in SFTS patients. The need for targeted treatment of EBV infection remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.